PRAC meeting highlights 29 August - 1 September 2022

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the August/September 2022 meeting describes the start of two separate reviews into topiramate use in pregnancy and women of childbearing potential, and medicines that contain pholcodine following concerns that their use may put people at risk of developing anaphylactic reactions (a sudden, severe and life-threatening allergic reaction) to neuromuscular blocking agents (NMBA).